Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

By importing foreign price controls for drugs, he’s compounding making Biden’s mistake.

In The Star's annual year in review, the county's biggest business stories included housing proposals and the aftermath of a ...